[
    [
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347.HK)获贝莱德增持3.31万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "贝莱德",
                    "增持"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)获贝莱德增持3.31万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒指收跌0.45%，地产、金融逆势走强",
            "features": {
                "keywords": [
                    "恒指",
                    "收跌",
                    "地产",
                    "金融",
                    "走强"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "地产",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒指收跌0.45%，地产、金融逆势走强",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【异动股】泰格医药(03347.HK)跌3.33%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】泰格医药(03347.HK)跌3.33%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "干货！2021年中国医药研发外包(CRO)行业龙头企业分析——药明康德：行业中的“领军者”",
            "features": {
                "keywords": [
                    "医药研发外包",
                    "CRO",
                    "药明康德",
                    "龙头企业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "干货！2021年中国医药研发外包(CRO)行业龙头企业分析——药明康德：行业中的“领军者”",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]